EMA Authorised: Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) — Holostem s.r.l.

View source ↗

Summary

The European Medicines Agency authorised Holoclar, an autologous stem cell-based therapy for repairing the corneal surface in patients with limbal stem cell def…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Disease
• Limbal Stem Cell Deficiency

Drugs mentioned

• Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)

Snippet

Status: Authorised. Therapeutic area: Stem Cell Transplantation;Corneal Diseases. MAH: Holostem s.r.l.. Decision date: 07/07/2025